Your browser doesn't support javascript.
Longitudinal profiles of plasma gelsolin, cytokines and antibody expression predict COVID-19 severity and hospitalization outcomes.
Asare-Werehene, Meshach; McGuinty, Michaeline; Vranjkovic, Agatha; Galipeau, Yannick; Cowan, Juthaporn; Cameron, Bill; Cooper, Curtis L; Langlois, Marc-André; Crawley, Angela M; Tsang, Benjamin K.
  • Asare-Werehene M; Department of Obstetrics & Gynecology, University of Ottawa, Ottawa, ON, Canada.
  • McGuinty M; Department of Cellular & Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
  • Vranjkovic A; Centre for Infection, Immunity & Inflammation, University of Ottawa, Ottawa, ON, Canada.
  • Galipeau Y; Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Cowan J; Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
  • Cameron B; Department of Biochemistry, Microbiology & Immunology, University of Ottawa, Ottawa, ON, Canada.
  • Cooper CL; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Langlois MA; Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Crawley AM; Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
  • Tsang BK; Department of Biochemistry, Microbiology & Immunology, University of Ottawa, Ottawa, ON, Canada.
Front Immunol ; 13: 1011084, 2022.
Article in English | MEDLINE | ID: covidwho-2312677
ABSTRACT

Background:

Prognostic markers for COVID-19 disease outcome are currently lacking. Plasma gelsolin (pGSN) is an actin-binding protein and an innate immune marker involved in disease pathogenesis and viral infections. Here, we demonstrate the utility of pGSN as a prognostic marker for COVID-19 disease outcome; a test performance that is significantly improved when combined with cytokines and antibodies compared to other conventional markers such as CRP and ferritin.

Methods:

Blood samples were longitudinally collected from hospitalized COVID-19 patients as well as COVID-19 negative controls and the levels of pGSN in µg/mL, cytokines and anti- SARS-CoV-2 spike protein antibodies assayed. Mean ± SEM values were correlated with clinical parameters to develop a prognostic platform.

Results:

pGSN levels were significantly reduced in COVID-19 patients compared to healthy individuals. Additionally, pGSN levels combined with plasma IL-6, IP-10 and M-CSF significantly distinguished COVID-19 patients from healthy individuals. While pGSN and anti-spike IgG titers together strongly predict COVID-19 severity and death, the combination of pGSN and IL-6 was a significant predictor of milder disease and favorable outcomes.

Conclusion:

Taken together, these findings suggest that multi-parameter analysis of pGSN, cytokines and antibodies could predict COVID-19 hospitalization outcomes with greater certainty compared with conventional clinical laboratory markers such as CRP and ferritin. This research will inform and improve clinical management and health system interventions in response to SARS-CoV-2 infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Gelsolin / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.1011084

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Gelsolin / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.1011084